Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To review the clinical effectiveness and cost-effectiveness of ivacaftor for the treatment of CF in patients aged 6 years who have the G551D mutation.

Authors' conclusions
The available evidence suggests that ivacaftor is a clinically effective treatment for patients with CF and the G551D mutation; the high cost of ivacaftor may prove an obstacle in the uptake of this treatment. The main priority for further research is the long-term effectiveness of ivacaftor.

Final publication URL
http://www.journalslibrary.nihr.ac.uk/hta/hta18180/#/abstract

Additional data URL
http://www.journalslibrary.nihr.ac.uk/hta/volume-18/issue-18#hometab0

Indexing Status
Subject indexing assigned by CRD

MeSH
Cystic Fibrosis; Aminophenols; Quinolones; Cystic Fibrosis Transmembrane Conductance Regulator; Mutation

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32013001082

Date abstract record published
03/01/2014